[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sangamo Therapeutics Inc (SGMO)

Sangamo Therapeutics Inc (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 30,657
  • Shares Outstanding, K 414,289
  • Annual Sales, $ 39,550 K
  • Annual Income, $ -122,930 K
  • EBIT $ -110 M
  • EBITDA $ -103 M
  • 60-Month Beta 1.30
  • Price/Sales 1.83
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.34
  • Most Recent Earnings $-0.08 on 05/14/26
  • Next Earnings Date 08/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 688.63% (+347.94%)
  • Historical Volatility 272.67%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 688.63% on 06/23/26
  • IV Low 88.05% on 07/14/25
  • Expected Move (DTE 57) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 90
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 60,049
  • Open Int (30-Day) 61,573
  • Expected Range 0.0740 to 0.0740

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.08
  • Growth Rate Est. (year over year) +1,248,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0637 +16.17%
on 06/23/26
0.2525 -70.69%
on 05/29/26
-0.1003 (-57.54%)
since 05/22/26
3-Month
0.0637 +16.17%
on 06/23/26
0.4084 -81.88%
on 03/25/26
-0.2610 (-77.91%)
since 03/23/26
52-Week
0.0637 +16.17%
on 06/23/26
0.7660 -90.34%
on 09/29/25
-0.3580 (-82.87%)
since 06/23/25

Most Recent Stories

More News
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

Sangamo intends to complete asset sale transactions through a voluntary Chapter 11 reorganization, in an effort to maximize business value for all stakeholders Lilly and Astellas to serve as “stalking...

SGMO : 0.0740 (-57.54%)
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the company’s...

SGMO : 0.0740 (-57.54%)
Sangamo: Q1 Earnings Snapshot

Sangamo: Q1 Earnings Snapshot

SGMO : 0.0740 (-57.54%)
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503...

SGMO : 0.0740 (-57.54%)
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

RICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its...

SGMO : 0.0740 (-57.54%)
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has...

SGMO : 0.0740 (-57.54%)
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq...

SGMO : 0.0740 (-57.54%)
Sangamo: Q4 Earnings Snapshot

Sangamo: Q4 Earnings Snapshot

SGMO : 0.0740 (-57.54%)
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all...

SGMO : 0.0740 (-57.54%)
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter...

SGMO : 0.0740 (-57.54%)

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 0.1644
2nd Resistance Point 0.1422
1st Resistance Point 0.1081
Last Price 0.0740
1st Support Level 0.0518
2nd Support Level 0.0296
3rd Support Level N/A

See More

52-Week High 0.7660
Fibonacci 61.8% 0.4977
Fibonacci 50% 0.4148
Fibonacci 38.2% 0.3320
Last Price 0.0740
52-Week Low 0.0637

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.